Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide and is often associated with aspects of metabolic syndrome. Despite its …

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …

Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …

Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic
syndrome. It represents a wide spectrum of histopathological abnormalities ranging from …

Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is
the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with an
estimated rising prevalence, in concert with the epidemics of obesity and type 2 diabetes …

The correct identification of patients at increased risk of non-alcoholic steatohepatitis
(NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis,
nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of …

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death.
Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the US population and …

Objective To examine the traditional diet-heart hypothesis through recovery and analysis of
previously unpublished data from the Minnesota Coronary Experiment (MCE) and to put …